Can Financial Statements From 2010 to 2025
| CANF Stock | 1.00 0.00 0.00% |
Check Can Fite financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Can Fite's main balance sheet or income statement drivers, such as , as well as many indicators such as . Can financial statements analysis is a perfect complement when working with Can Fite Valuation or Volatility modules.
Can |
Can Fite Biopharma Company Current Valuation Analysis
Can Fite's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Can Fite Current Valuation | 35.67 M |
Most of Can Fite's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Can Fite Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Can Fite Biopharma has a Current Valuation of 35.67 M. This is 99.75% lower than that of the Biotechnology sector and 99.23% lower than that of the Health Care industry. The current valuation for all Israel stocks is 99.79% higher than that of the company.
Can Fite Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Can Fite's current stock value. Our valuation model uses many indicators to compare Can Fite value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Can Fite competition to find correlations between indicators driving Can Fite's intrinsic value. More Info.Can Fite Biopharma is rated second in return on equity category among its peers. It is rated fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Can Fite by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Can Fite's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Can Fite Financial Statements
Can Fite stakeholders use historical fundamental indicators, such as Can Fite's revenue or net income, to determine how well the company is positioned to perform in the future. Although Can Fite investors may analyze each financial statement separately, they are all interrelated. For example, changes in Can Fite's assets and liabilities are reflected in the revenues and expenses on Can Fite's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Can Fite Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel. CAN FITE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 7 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Can Stock
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out the analysis of Can Fite Correlation against competitors. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.